Sign up for your free ClinicalKey trial today! Your first step in getting the right answers
when you need them.
Complications and Prognosis
Screening and Prevention
Mild to moderate disease
Relapse prevention r25
Esketamine nasal spray—the first N-methyl-D-aspartate receptor antagonist to receive FDA approval for major depression—can be used as an adjunct to an oral antidepressant for major depression with acute suicidal ideation or behavior or treatment-resistant depression r28r29
Cookies are used by this site. To decline or learn more, visit our cookie notice.